UY25421A1 - Antagonistas de receptor de vitronectina - Google Patents

Antagonistas de receptor de vitronectina

Info

Publication number
UY25421A1
UY25421A1 UY25421A UY25421A UY25421A1 UY 25421 A1 UY25421 A1 UY 25421A1 UY 25421 A UY25421 A UY 25421A UY 25421 A UY25421 A UY 25421A UY 25421 A1 UY25421 A1 UY 25421A1
Authority
UY
Uruguay
Prior art keywords
vitronectin receptor
receptor antagonists
stenosis
osteoporosis
atherosclerosis
Prior art date
Application number
UY25421A
Other languages
English (en)
Spanish (es)
Inventor
W Miller J Gleason D Uzinskas
Peter J Manley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Priority to UY25519A priority Critical patent/UY25519A1/es
Publication of UY25421A1 publication Critical patent/UY25421A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
UY25421A 1998-03-10 1999-03-10 Antagonistas de receptor de vitronectina UY25421A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY25519A UY25519A1 (es) 1998-03-10 1999-05-19 Procedimiento para preparar antagonista del receptor de vitronectina

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US9606398P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
UY25421A1 true UY25421A1 (es) 2001-07-31

Family

ID=26759473

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25421A UY25421A1 (es) 1998-03-10 1999-03-10 Antagonistas de receptor de vitronectina
UY25519A UY25519A1 (es) 1998-03-10 1999-05-19 Procedimiento para preparar antagonista del receptor de vitronectina

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY25519A UY25519A1 (es) 1998-03-10 1999-05-19 Procedimiento para preparar antagonista del receptor de vitronectina

Country Status (24)

Country Link
EP (1) EP1061921A4 (no)
JP (1) JP2002506033A (no)
KR (1) KR20010041812A (no)
CN (1) CN1299282A (no)
AP (1) AP2000001898A0 (no)
AR (1) AR015241A1 (no)
AU (1) AU758498B2 (no)
BG (1) BG104824A (no)
BR (1) BR9908636A (no)
CA (1) CA2323208A1 (no)
CO (1) CO5080762A1 (no)
DZ (1) DZ2741A1 (no)
EA (1) EA200000921A1 (no)
HU (1) HUP0101143A3 (no)
ID (1) ID26223A (no)
IL (1) IL138245A0 (no)
NO (1) NO20004503L (no)
OA (1) OA12189A (no)
PE (1) PE20000323A1 (no)
PL (1) PL342881A1 (no)
SK (1) SK13292000A3 (no)
TR (1) TR200002625T2 (no)
UY (2) UY25421A1 (no)
WO (1) WO1999045927A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US20070275956A1 (en) * 2003-10-14 2007-11-29 Lohray Braj B Novel Heterocyclic Compounds
JP4853284B2 (ja) * 2004-03-05 2012-01-11 大正製薬株式会社 チアゾール誘導体
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080004554A (ko) 2005-04-20 2008-01-09 얀센 파마슈티카 엔.브이. 불소화 피리딘 n―옥사이드 트롬빈 모듈레이터 및 질소를함유하는 헤테로아릴의 n―산화 방법
EP3040329B1 (en) * 2013-08-29 2018-10-10 Kyoto Pharmaceutical Industries, Ltd. Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism
PT3929196T (pt) 2013-09-24 2023-09-11 Fujifilm Corp Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1209063A (zh) * 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
KR19990076876A (ko) * 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제

Also Published As

Publication number Publication date
KR20010041812A (ko) 2001-05-25
AU758498B2 (en) 2003-03-20
CN1299282A (zh) 2001-06-13
UY25519A1 (es) 1999-12-13
CO5080762A1 (es) 2001-09-25
DZ2741A1 (fr) 2003-09-08
JP2002506033A (ja) 2002-02-26
EP1061921A4 (en) 2005-03-30
BR9908636A (pt) 2002-01-08
WO1999045927A1 (en) 1999-09-16
NO20004503D0 (no) 2000-09-08
AP2000001898A0 (en) 2000-09-30
AR015241A1 (es) 2001-04-18
PE20000323A1 (es) 2000-05-24
OA12189A (en) 2006-05-09
HUP0101143A3 (en) 2002-12-28
IL138245A0 (en) 2001-10-31
SK13292000A3 (sk) 2001-06-11
EP1061921A1 (en) 2000-12-27
EA200000921A1 (ru) 2001-04-23
ID26223A (id) 2000-12-07
TR200002625T2 (tr) 2000-12-21
AU2903399A (en) 1999-09-27
NO20004503L (no) 2000-10-10
BG104824A (en) 2001-05-31
CA2323208A1 (en) 1999-09-16
PL342881A1 (en) 2001-07-16
HUP0101143A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
UY25421A1 (es) Antagonistas de receptor de vitronectina
AR010873A1 (es) Compuestos antagonistas del receptor de vitronectina, intermediarios, metodos de su preparacion, composiciones farmaceuticas, uso de dichoscompuestos para la fabricacion de medicamentos.
ES2134859T3 (es) Derivados de 4-carboxoamido-piperidina, productos intermedios y uso como antagonistas de neurokinina.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2194223T3 (es) Antagonistas de la integrina.
ES2074736T3 (es) Procedimiento para la produccion de polifluoroolefinas.
ATE294163T1 (de) Integrin-rezeptor-antagonisten
PA8452701A1 (es) Agonistas de prostaglandinas
IS5513A (is) Intergrín viðtaka mótlyf
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
ATE299023T1 (de) Integrinrezeptor antagonisten
BR0310087A (pt) Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
SI1893237T1 (sl) Farmacevtska zmes ki vsebuje organopolisiloksan elastomer in učinkovino v obliki raztopine
DE60015508D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
UY25824A1 (es) Antagonista del receptor de vitronectina
DK1756046T3 (da) Arylalkylsulfonamider som terapeutiske midler til behandling af knoglelidelser
AR025589A1 (es) Antagonistas de los receptores de vitronectina.
ECSP003747A (es) Metodo y composiciones para el tratamiento de las enfermedades pulmonares
GT199900083A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica.
WO2001032197A3 (en) Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
AR042065A1 (es) Un metodo para preparar acido indano-1,3- dicarboxilico
UY26651A1 (es) Terapia combinada para la osteoporosis
NZ506750A (en) Vitronectin receptor antagonists useful in the treatment of inflammation, cancer and cardiovascular disorders
GB0422929D0 (en) Bioactive vitamin D analogues

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090715